MRSA (methicillin-resistant staphylococcus aureus)

MRSA is presently a pathogen of global health concern. . They are S. aureus strains that are resistant to oxacillin, nafcillin and methicillin. They can also be resistant to all ß-lactam agents.  It can cause a variety of problems ranging from skin infections and sepsis to pneumonia and various types of bloodstream infections. The infections occur commonly among people in hospitals and healthcare facilities such as nursing homes, diagnostic centres and dialysis centres, who have less stable immune systems. The current arsenal of antibiotics available for the treatment of MRSA includes a topical agent, a limited number of oral agents.

 

  • Community-acquired MRSA (CA-MRSA)
  • Healthcare-associated MRSA (HA-MRSA)
  • Virulence Associated Factors of CA-MRSA
  • Antibiotic resistance
  • Recurrent MRSA Infections
  • Oral and intravenous agents
  • Topical agents
  • Vancomycin, Clindamycin and linezolid
  • Pneumonia (HAP/VAP)
  • Chronic osteomyelitis (COM)
  • Skin and soft tissue infections

Related Conference of MRSA (methicillin-resistant staphylococcus aureus)

May 18-19, 2026

15th World Congress on Rare Diseases and Orphan Drugs

Prague, Czech Republic
June 29-30, 2026

7th Global Experts Meeting on Infectious Diseases

Singapore City, Singapore
August 25-26, 2026

18th Global Conference on Nephrology and Infectious Diseases

Amsterdam, Netherlands

MRSA (methicillin-resistant staphylococcus aureus) Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in